TRVI News and Press, Trevi Therapeutics Inc. From 03/20/24

2024-03-20 18:21:10 ET Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Conference Call March 20, 2024 04:30 PM ET Company Participants Jennifer Good - President & CEO Lisa Delfini - CFO David Clark - Chief Medical Officer Conference Call Participants ...

2024-03-20 16:52:24 ET Gainers: Micron Technology ( MU ) +13% . Accuray  ( ARAY ) +5% . Western Digital Corporation ( WDC ) +4% . AXT ( AXTI ) +4% . Intapp ( INTA ) +3% . Losers: Five Below ( FIVE ) -13% . ...

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressi...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 PR Newswire Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. , March 13, 2024 /PRNewswire/ -- Trevi T...

Trevi Therapeutics to Participate in Upcoming March Events PR Newswire NEW HAVEN, Conn. , Feb. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire Corporate presentation will be held on Wednesday, February 14, 2024 , at 10:00 a.m. ET NEW HAVEN, Conn. , Feb. 6, 2024 /PRNewswire/ --...

Trevi Therapeutics Provides Business Updates PR Newswire NEW HAVEN, Conn. , Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbu...

Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire Expect to enroll approximately 160 subjects and study 3 doses of Haduvio against placebo Primary eff...

2023-11-12 05:46:03 ET Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Conference Call November 09, 2023, 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Off...